Marshall Wace LLP Takes Position in Omeros Co. (NASDAQ:OMER)

Marshall Wace LLP bought a new stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,205 shares of the biopharmaceutical company's stock, valued at approximately $437,000. Marshall Wace LLP owned 0.08% of Omeros as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Truvestments Capital LLC grew its stake in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros during the 4th quarter valued at approximately $46,000. Picton Mahoney Asset Management increased its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. US Bancorp DE purchased a new stake in Omeros in the fourth quarter valued at $81,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Omeros during the 4th quarter worth $121,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

Wall Street Analysts Forecast Growth

OMER has been the topic of several research analyst reports. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Wednesday. StockNews.com lowered Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, April 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Omeros has an average rating of "Moderate Buy" and an average price target of $22.50.

Omeros Trading Up 0.3 %

Shares of NASDAQ:OMER traded up $0.02 on Friday, hitting $6.33. The company had a trading volume of 201,967 shares, compared to its average volume of 595,859. The company has a market cap of $369.08 million, a PE ratio of -2.74 and a beta of 2.42. The business has a 50 day moving average of $7.47 and a 200 day moving average of $8.11. Omeros Co. has a 52-week low of $3.00 and a 52-week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.08. During the same quarter in the previous year, the company earned ($0.15) earnings per share. As a group, equities analysts predict that Omeros Co. will post -3.09 EPS for the current year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.